Figure 1.
Seroprevalences of human polyomaviruses (PyV) as determined by VP1 seroreactivity among 229 controls by age group from the Skin Cancer Prevention Study, using the baseline or earliest serum sample collected. The overall seroprevalence (%) and number of participants who were seropositive for each PyV is shown above the bars. The number of participants within each age group is noted in the legend.